Croft Harry, Houser Trisha L, Jamerson Brenda D, Leadbetter Robert, Bolden-Watson Carolyn, Donahue Rafe, Metz Alan
Croft Group Research Center, San Antonio, Texas 78229, USA.
Clin Ther. 2002 Apr;24(4):662-72. doi: 10.1016/s0149-2918(02)85141-4.
Short-term studies have demonstrated a modest weight-reducing to weight-neutral effect among patients receiving bupropion sustained-release (SR) for the treatment of depression.
This study was conducted to evaluate the long-term effects of bupropion SR on body weight in patients with depression.
This analysis was conducted within a long-term relapse-prevention study in patients with major depression. Those whose depression had responded to open-label treatment with bupropion SR were randomized to 44 weeks of double-blind treatment with bupropion SR 300 mg/d or placebo. Patients were categorized by body mass index (BMI) as follows: BMI < 22, BMI 22 to 26, BMI > or = 27, and BMI > or = 30.
Four hundred twenty-three patients were enrolled in the double-blind phase of the study, 210 receiving bupropion SR and 213 receiving placebo. At the end of the open-label phase, the following mean weight losses were seen in the 4 BMI groups: BMI < 22, 0.5 kg; BMI 22 to 26, 1.1 kg; and BMI > or = 27 and BMI > or = 30, 1.8 kg each. At the end of double-blind treatment, mean change-from-baseline weights were as follows: BMI < 22, -0.1 kg; BMI 22 to 26, -0.6 kg; BMI > or = 27, -1.4 kg; and BMI > or = 30, -2.4 kg. The rate of change in body weight during the double-blind phase was statistically significant compared with baseline BMI (P < 0.001, analysis of covariance).
Modest mean weight losses that increased with increasing baseline body weight were observed with long-term bupropion SR treatment. The findings of this analysis suggest that bupropion SR may be an appropriate therapeutic option in normal-weight or overweight patients with depression who are concerned about weight gain.
短期研究表明，接受安非他酮缓释剂（SR）治疗抑郁症的患者有适度的体重减轻至体重中性效应。
本研究旨在评估安非他酮SR对抑郁症患者体重的长期影响。
本分析在一项针对重度抑郁症患者的长期预防复发研究中进行。那些抑郁症对安非他酮SR开放标签治疗有反应的患者被随机分为接受300mg/d安非他酮SR或安慰剂的双盲治疗44周。患者按体重指数（BMI）分类如下：BMI<22、BMI 22至26、BMI≥27和BMI≥30。
423名患者进入研究的双盲阶段，210名接受安非他酮SR，213名接受安慰剂。在开放标签阶段结束时，4个BMI组的平均体重减轻如下：BMI<22，0.5kg；BMI 22至26，1.1kg；BMI≥27和BMI≥30，均为1.8kg。在双盲治疗结束时，与基线体重相比的平均体重变化如下：BMI<22，-0.1kg；BMI 22至26，-0.6kg；BMI≥27，-1.4kg；BMI≥30，-2.4kg。双盲阶段体重变化率与基线BMI相比有统计学意义（P<0.001，协方差分析）。
长期使用安非他酮SR治疗观察到适度的平均体重减轻，且随着基线体重的增加而增加。该分析结果表明，安非他酮SR可能是担心体重增加的正常体重或超重抑郁症患者的合适治疗选择。
